Baird Financial Group
NEOS

Baird Financial Group’s Neos Therapeutics, Inc NEOS Stock Holding History

Baird Financial Group’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-34,737
Closed -$45K – 1575
2019
Q2 		$45K Buy
+34,737
New +$63.9K ﹤0.01% 1515

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Baird Financial Group's NEOS Position: Q3 2019 in Review

Baird Financial Group sold out of Neos Therapeutics, Inc (NEOS) in Q3 2019, closing a stake of 34,737 shares — an estimated $45K sold.

Baird Financial Group first reported a position in NEOS in Q2 2019 and held it in 1 quarter. The position peaked at $45K in Q2 2019. 51 funds tracked by Wall St. Rank hold NEOS as of Q3 2019.

  • Baird Financial Group reported no remaining Neos Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Baird Financial Group sold 34,737 Neos Therapeutics, Inc shares in Q3 2019, an estimated $45K.
  • Baird Financial Group first reported a position in Neos Therapeutics, Inc in Q2 2019 and held it in 1 quarter.
  • Baird Financial Group's Neos Therapeutics, Inc position peaked at $45K in Q2 2019.
  • 51 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2019.

Based on Baird Financial Group's 13F filing for Q3 2019, filed 14 Nov 2019.